Download PDF
CC BY-NC-ND 4.0 · Arch Plast Surg 2022; 49(03): 457-461
DOI: 10.1055/s-0042-1748664
Extremity/Lymphedema
Case Report

Misdiagnosis of Human Herpes Virus-8-Associated Kaposi's Sarcoma as Adverse Drug Eruptions

Tae Hyung Kim 
1   Department of Plastic and Reconstructive Surgery, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Republic of Korea
,
Syeo Young Wee 
1   Department of Plastic and Reconstructive Surgery, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Republic of Korea
,
Hyun Gyo Jeong 
1   Department of Plastic and Reconstructive Surgery, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Republic of Korea
,
Hwan Jun Choi 
2   Department of Plastic and Reconstructive Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea
› Author Affiliations Funding This work was supported by the National Research Foundation of Korea grant funded by the Korea government (MSIT; 2020R1A2C1100891), and was supported by Soonchunhyang University research fund.
› Further Information
   Permissions and Reprints

Abstract

Kaposi's sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin. It also occurs in the immunosuppressive population. KS is currently believed to be caused by infection with human herpes virus-8 (HHV-8) in non-human immunodeficiency virus patient. A 79-year-old female visited the outpatient clinic presenting with increasing number and size of palpable masses on both upper and lower extremities. She was first diagnosed as drug-erupted dermatitis and stopped her medications, but the symptoms got worse. We did partial biopsy, and KS with HHV-8 was diagnosed histopathologically. She planned to undergo further evaluations and proper treatments. This rare case suggests the need to consider a classic type of KS in the differential diagnosis of specific dermatologic symptoms such as macular, nodular, and darkish patches of upper or lower extremities in elderly patients. It is believed that this case helps to strengthen awareness of this rare disease.

Keywords

extremities - non-AIDS-related Kaposi sarcoma - adverse drug reactions

Author Contributions

Conceptualization : H.J.C. Writing-original draft : T.H.K. Writing-review and editing: H.G.J. and S.Y.W. All authors read and approved the final manuscript.


Ethical Approval

This study was approved by the Institutional Review Board of Soonchunhyang University Cheonan Hospital (IRB No. 2020–11–056) and performed in accordance with the principles of the Declaration of Helsinki. The patient provided informed consent to publish.


Patient Consent

Informed consent was obtained from all individual participants included in the study.




Publication History

Article published online:
27 May 2022

© 2022. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Nickoloff BJ, Foreman KE. Etiology and pathogenesis of Kaposi's sarcoma. In: Dummer R, Nestle FO, Burg G. eds. Cancers of the Skin. vol. 160, Berlin, Heidelberg: Springer; 2002: 331-342
    Google Scholar
  • 2 Kamiyango W, Villiera J, Silverstein A, Peckham-Gregory E, Campbell LR, El-Mallawany NK. Navigating the heterogeneous landscape of pediatric Kaposi sarcoma. Cancer Metastasis Rev 2019; 38 (04) 749-758
    CrossrefPubMedGoogle Scholar
  • 3 Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993; 28 (03) 371-395
    CrossrefPubMedGoogle Scholar
  • 4 Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol 2004; 87 (03) 146-151
    CrossrefPubMedGoogle Scholar
  • 5 Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol 2008; 53 (01) 2-8
    CrossrefPubMedGoogle Scholar
  • 6 Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol 2019; 58 (05) 538-542
    CrossrefPubMedGoogle Scholar
  • 7 Rescigno P, Di Trolio R, Buonerba C. et al. Non-AIDS-related Kaposi's sarcoma: a single-institution experience. World J Clin Oncol 2013; 4 (02) 52-57
    CrossrefPubMedGoogle Scholar
  • 8 Lanternier F, Lebbé C, Schartz N. et al. Kaposi's sarcoma in HIV-negative men having sex with men. AIDS 2008; 22 (10) 1163-1168
    CrossrefPubMedGoogle Scholar
  • 9 Krown SE, Lee JY, Lin L. et al. Interferon-a2b with protease inhibitor–based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma. J Acquir Immune Defic Syndr 2006; 41: 5
    CrossrefPubMedGoogle Scholar
  • 10 Oyucu Orhan S, Bilgehan Sahin A, Cubukcu E. et al. Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: a single-center retrospective real-world data. Bosn J Basic Med Sci 2021; 21 (06) 746-751
    PubMedGoogle Scholar
  • 11 Reid E, Suneja G, Ambinder RF. et al; CGC. AIDS-related Kaposi sarcoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17 (02) 171-189
    CrossrefPubMedGoogle Scholar
  • 12 Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi sarcoma. Am J Clin Dermatol 2017; 18 (04) 529-539
    CrossrefPubMedGoogle Scholar
  • 13 Krown SE, Moser CB, MacPhail P. et al; A5263/AMC066 protocol team. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet 2020; 395 (10231): 1195-1207
    CrossrefPubMedGoogle Scholar
  • 14 Tsao MN, Sinclair E, Assaad D. et al. Radiation therapy for the treatment of skin Kaposi sarcoma. Ann Palliat Med 2016; 5 (04) 298-302
    CrossrefPubMedGoogle Scholar
  • 15 Lebbe C, Garbe C, Stratigos AJ. et al; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer 2019; 114: 117-127
    CrossrefPubMedGoogle Scholar